Japan· JP-2190047M3026
マバカムテン
A mavacamten product containing マバカムテン, registered in Japan by ブリストル・マイヤーズ スクイブ, on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Mavacamten is registered in 15 of 19 countries.
Countries holding a registration under ATC C01EB24 (mavacamten), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Mavacamten · ATC C01EB24
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mavacamten costs, country by country.
Normalised to the WHO defined daily dose (5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mavacamten · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$118.52
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- マバカムテン
- Manufacturer
- ブリストル・マイヤーズ スクイブ
- Country
- Japan (JP)
- ATC code
- C01EB24
- ATC class
- Mavacamten
- Defined daily dose
- 5 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under C01EB24
Mavacamten, as other registers publish it.
- IcelandCamzyosBristol-Myers Squibb Pharma EEIG*
- IcelandCamzyosBristol-Myers Squibb Pharma EEIG*
- PolandCamzyosBristol-Myers Squibb Pharma EEIG
- PolandCamzyosBristol-Myers Squibb Pharma EEIG
- PolandCamzyosBristol-Myers Squibb Pharma EEIG
- IcelandCamzyosBristol-Myers Squibb Pharma EEIG*
- NorwayCamzyosBristol-Myers Squibb Pharma EEIG
- SwitzerlandCamzyos
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ff92a811-9bca-4fe4-a50c-5a5292169b9b GET /v1/drugs/ff92a811-9bca-4fe4-a50c-5a5292169b9b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５ｍｇ１カプセル",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2190047M3026",
"category": "内用薬",
"price_yen": 7410.5,
"generic_name": "マバカムテン",
"product_name_jp": null,
"therapeutic_class": "2190",
"transitional_expiry": null
}See everything about mavacamten.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.